New drug cocktail aims to stop triple negative breast cancer from returning

NCT ID NCT07679360

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a combination of two drugs, trastuzumab rezetecan and adebrelimab, can prevent breast cancer from returning in people with triple negative breast cancer who still have cancer cells after initial chemotherapy and surgery. The study compares this new combination to standard treatments chosen by the doctor. About 1000 participants will be randomly assigned to receive either the experimental combination or a standard therapy, and researchers will track how long they live without the cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Trastuzumab Rezetecan and Adebrelimab
What this could lead to
If successful, this combination could offer a more effective treatment option for triple negative breast cancer patients who still have cancer after initial therapy, potentially reducing the risk of recurrence.
What could go wrong
This is an early-stage Phase 3 trial, and the combination may not prove more effective than existing treatments. Side effects from the drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cancer Hospital of Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.